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ABSTRACT
Aims: To determine whether edaravone (MCI-186), a free
radical scavenger, can reduce macular oedema and
improve the visual acuity after arteriovenous sheathotomy
in eyes with a branch retinal vein occlusion (BRVO).
Methods: Forty-seven eyes of 47 consecutive patients
with a BRVO who were treated with arteriovenous
sheathotomy were studied. The patients were assigned
prospectively to either Group R who received 30 mg of
edaravone (Radicut) systemically during the vitrectomy or
Group N who did not receive any drugs. The postoperative
visual acuity was measured before and 12 months after
the operation.
Results: At 12 months postoperatively, the best-
corrected visual acuity (BCVA) in logarithm of the
minimum angle of resolution (logMAR) units improved
significantly from 0.22 to 0.56 logMAR units in Group R
and from 0.20 to 0.27 units in Group N (p=0.016).
Twenty-three of 27 cases (85%) in Group R and four of 15
cases (27%) in Group N showed an improvement in BCVA
of .0.2 logMAR units (p=0.0025).
Conclusion: The better visual acuity in patients given
edaravone than those without endaravone during the
arteriovenous sheathotomy suggests that edaravone
improved the physiology of the retinal cells after the
arteriovenous sheathotomy.
Earlier studies have shown that vitrectomy is
effective in reducing the macular oedema asso-
ciated with a branch retinal vein occlusion
(BRVO).
12The surgical procedures used to treat a
BRVO during vitrectomy have been broadened to
include creating a posterior vitreous detachment,
3
removal of the inner-limiting-membrane
4 and
administration of intravitreal triamcinolone acet-
onide (TA).
5 It has been proposed that the
reduction of macular oedema by vitrectomy was
due to the release of vitreal traction on the retina
and an enhancement of the cytokine metabolism.
6
TA and anti-vascular endothelial growth factor
(VEGF) have been given to reduce the permeability
of the retinal veins caused by the BRVO.
A more recent adjunctive procedure used during
the vitrectomy is arteriovenous sheathotomy. The
rationale for this procedure is that it reduces or
eliminates the pressure on the retinal vein at the
arteriovenous crossing caused by the BRVO.
78In
addition, it was expected that a combination of
arteriovenous sheathotomy and vitrectomy would
result in a greater reduction in BRVO-associated
macular oedema.
9 However, the results showed
that the postoperative visual acuity was not
significantly improved.
10 Even in studies in which
the reperfusion of the occluded retinal vein was
accomplished, a reduction of macular oedema and
an improvement of the visual acuity were not
always obtained.
11
Free radicals are often produced in patients with a
cerebral infarction, and the free radicals can then
damage endothelial cells and neurocytes during the
reperfusion.
12 13 A recent study showed that hydro-
xyl radicals were generated in the retina during an
ischaemic episode and remained elevated during the
reperfusion period.
14 15 T h e s eh y d r o x y lr a d i c a l sc a n
be inactivated by reactive oxygen species scavengers,
such as superoxide dismutase and catalase.
16
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-
one), a free radical scavenger, was developed in
Japan as a neuroprotective agent against the free
radicals generated by ischaemia.
17 Edavarone is an
electron donor and when it interacts with free
radicals, the reaction yields a peroxyl anion and an
edaravone radical, which is then transformed into
4,5-dione. The hydrolysis of 4,5-dione gives 2-oxo-
3-phenylhydrazono-butanoic acid.
18 Edaravone
blocks both the water-soluble and lipid-soluble
peroxyl radical-induced peroxidation systems.
Arteriovenous sheathotomy for the treatment of
BRVO generates free radicals during the reperfu-
sion that may damage the retinal cells and affect
the postoperative visual acuity. Thus, the purpose
of this study was to determine whether a systemic
administration of edaravone during vitrectomy
would enhance the recovery of vision after
arteriovenous sheathotomy for the treatment of
macular oedema associated with BRVO.
MATERIALS AND METHODS
Forty-seven eyes of 47 consecutive patients who had
undergone vitrectomy for BRVO combined with
arteriovenous sheathotomy between February 2003
and December 2005 in Tane Memorial Hospital,
Osaka,Japan, were studied.All patients had macular
oedema with or without a haemorrhage in the
macular region accompanying the BRVO, and had a
preoperative best-corrected visual acuity (BCVA)
(20/40. Preoperative fluorescence angiography (FA)
showed fluorescein dye leakage from the vein at the
arteriovenous crossing in all patients. There were 24
men and 23 women, ranging in age from 41 to 78
years. The best estimated intervalbetween the onset
oftheBRVOonsetandtheinitialexamination was4
to 50 months.
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consequences of the surgery were explained to each patient. The
patients were assigned to two groups prospectively: Group R
consisted of 30 consecutive patients who were treated between
February 2003 and December 2004 and received 30 mg
edaravone; Group N consisted of 17 consecutive patients who
were treated between January 2005 to December 2005 and did
not receive any drugs. In Group R, 30 mg of edaravone was
dissolved in 100 ml of sterile physiological saline and adminis-
tered intravenously over a period of 2 h at the beginning of
surgery.
A standard 20 gauge, three-port vitrectomy was performed
with an intentional posterior vitreous separation using a
vitreous cutter in eyes without a posterior vitreous detachment.
Arteriovenous sheathotomy was performed at the arteriovenous
crossing with a BRVO knife (DORC Co., Ltd., Zuidland,
Holland; fig 1). All eyes were treated by the same surgeon (T
M). None of the patients was given TA before, during or after
the surgery. Photocoagulation was not used to treat any of the
patients. All of the patients were phakic and had only a mild
cataract that did not affect the preoperative visual acuity. The
inner limiting membrane was not removed, and none of the
patients underwent a cataract operation postoperatively. None
of the patients required a gas tamponade. At the end of the
surgery, all eyes were treated with a topical antibiotic ointment
and 0.1% fluorometholone for 4 weeks. On days 1 and 2 after
the surgery, edaravone was given intravenously over a 2 h
period twice a day as done preoperatively to the patients in
Group R.
There were no significant differences in the estimated duration
of the BRVO, average age or sex between the two groups. The
mean observation period was 11.3 (SD 1.7) months and 42 of the
47patientswerefollowedfor12 monthsaftertheoperation. In all
patients, the visual acuity and macular oedema as evaluated by
leakage of fluorescein during fluorescein angiography were
measured before and after the operation, and the preoperative
and postoperative results were compared. Before and 12 months
after the operation, the assessment of the presence of fluorescein
leakage and the degree of macular oedema was made by trained
ophthalmologists who were masked to which group the eye
belonged. Before and 3 and 12 months after the operation, the
vision test was performed by examiners (who were masked to
which group the eye belonged to) with a Japanese Snellen chart,
and the values were converted to the logarithm of the minimum
angle of resolution (logMAR) units.
The visual acuity in logMAR units was used for the statistical
analyses. The differences in the mean visual acuity between the
two groups were analysed using the Student’s t test. An
improvement in the visual acuity was defined as an increase of
>0.2 logMAR units, while a decrease was defined as a reduction
of >0.2 logMAR units. The difference in the visual acuity
improvement ratio between the two groups was analysed using
the Mann–Whitney U test. The correlation between the
interval between the onset of symptoms and the surgery and
improvement of visual acuity was determined by the Kruskal–
Wallis test. Differences in the reduction in macular oedema
between the two groups were analysed using Fisher’s exact
probability test.
RESULTS
The intravenous edaravone did not cause any significant side
effects in any of the patients. During the follow-up period, none
of the patients developed a secondary cataract that affected the
visual acuity in both groups. The correlation between the
interval between the onset of symptoms and the surgery and
the improvement of visual acuity was not significant (p=0.30).
The artery and vein at the arteriovenous crossing was separated
by the sheathotomy in all subjects. An increase in the blood
flow through the occluded vein postoperatively was confirmed
in all subjects by fluorescein angiography at the last examina-
tion.
In Group R, the mean BCVA was 0.22 (SD 0.05) logMAR
units before the operation, and it improved to 0.42 (SD 0.05)
logMAR units at 3 months and 0.56 (SD 0.07) logMAR units at
12 months after the operation. In Group N, the mean BCVA
was 0.20 (SD 0.07) logMAR units before the operation, 0.30 (SD
0.07) logMAR units at 3 months, and 0.27 (SD 0.11) logMAR
units at 12 months postoperatively. The difference in the
preoperative mean visual acuity between the two groups was
not significant, but at 12 months after the surgery the mean
visual acuity was significantly better in Group R than in Group
N (p=0.086 at 3 months; p=0.016 at 12 months; fig 2).
At 12 months postoperatively, 23 of 27 eyes (85%) in Group
R had an improvement in the visual acuity >0.2 logMAR units,
three eyes (11%) were unchanged, and one eye (4%) had a
decrease of .0.2 logMAR units. In the 15 eyes in Group N, four
eyes (27%) showed an improvement of >0.2 logMAR units, ten
eyes (67%) were unchanged, and one eye (6%) had a decrease of
.0.2 logMAR units in the visual acuity. The percentage of eyes
with an improvement of visual acuity rate in Group R was
significantly higher in Group R than in Group N (p=0.0025;
fig 3).
Macular oedema was reduced in patients whose fluorescence
angiogram showed a reduction in postoperative leakage. Using
this definition for the 42 eyes that were followed for at least
Figure 1 Intraoperative photographs of
the fundus in an eye with a branch retinal
vein occlusion before (left) and after
(right) arteriovenous sheathotomy. A
restoration of blood flow after the
arteriovenous sheathotomy can be seen.
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macular oedema in 26 (96%) of 27 eyes in Group R, and in 11
(73%) of 15 eyes in Group N. This difference was significant
(p=0.047; fig 4).
DISCUSSION
There are conflicting results on the effectiveness of vitrectomy
against the macular oedema in eyes with a BRVO. Thus, an
earlier study reported that vitrectomy alone led to a reduction in
macular oedema and an improvement in visual acuity,
2 and later
clinical reports have also reported that arteriovenous sheathot-
omy was effective as an adjunct to vitrectomy in reducing
macular oedema.
78However, there are also some reports that
the decrease in macular oedema was not significant, or a
significant improvement of visual acuity was not attained
although a decrease of the macular oedema was obtained.
10
In eyes without a retrograde blood flow in the occluded vein
or without a collateral pathway preoperatively, arteriovenous
sheathotomy led to a restoration of blood flow downstream of
the arteriovenous crossing, ie a reperfusion. Even with an
improvement of venous blood flow, two factors need to be
considered to explain the macular oedema was not reduced and
the visual acuity not improved. First, the photoreceptor and
neural cells in the inner retina could have been irreversibly
damaged during the period of occlusion. Second, reperfusion can
generate free radicals that can damage neuronal and vascular
endothelial cells. These factors need to be considered when
assessing the efficacy of arteriovenous sheathotomy.
In our cases, the preoperative visual acuity, estimated
duration of the BRVO and degree of macular oedema between
the two groups were not significantly different. These
preoperative findings indicate that the physiological condition
of the photoreceptors and other retinal neurons was probably
similar in the two groups. However, our results showed that the
improvements in both visual acuity and macular oedema were
significantly better in patients in Group R than that in Group
N. This suggests that the decrease in these functions was due to
the effects of free radicals produced during the reperfusion.
It has been reported that the concentration of intracellular
calcium ions rises in the ischaemic retina, leading to successive
catalysis of calpaine, phospholipase A2 and nitric oxide
synthase,
19–22 and finally the production of superoxide anion,
hydrogen peroxide and hydroxyl radical during the reperfu-
sion.
15 In our cases, the arteriovenous sheathotomy can be
considered to be the procedure that led to the reperfusion and
the generation of the free radicals.
Edaravone was developed as an effective eliminator of the free
radicals produced at the acute stage of cerebral infarction that
would protect the ischaemic brain from oxidative damage.
17
Thus, the mechanism of edaravone treatment is different from
the conventional anticoagulant, platelet-aggregation inhibitor
and anti-VEGF treatments used in cases of vascular blockage.
Edaravone has a molecular mass of 174.20 Da and eliminates
hydroxyl radicals with strong oxidative power, as well as water-
soluble and liposoluble peroxyl radicals. This property of
edaravone arises because it is a free radical scavenger of the
electron-donor type. In contrast, the antioxidants vitamins E
and C, which act by donating a hydrogen atom, eliminate only
peroxyl radicals. Consequently, edaravone is considered to be
more effective as an eliminator of free radicals.
23
The patients in Group R who received 30 mg edaravone at
the start of the vitrectomy had significantly better visual acuity
at the final examination. This strongly suggests that the
improvement was caused by the reduction of free radical-
induced damage to neuronal cells and vascular endothelial
cells.
24 25 The reduction of macular oedema was caused by the
prevention of the damage to the vascular endothelial cells at the
early stage after the reperfusion.
It generally requires several months for the visual acuity to
improve after vitrectomy for vitreoretinal diseases. In our cases,
a statistically significant improvement in the mean visual acuity
was detected at 12 months after the surgery in Group R.
However, the difference in the mean visual acuity at 3 months
between Group R and Group N was not significant, which also
suggests that a longer time is required for visual acuity
improvement.
Figure 2 Changes in the best-corrected visual acuity in logarithm of the
minimum angle of resolution (logMAR) units before the operation, and at
3 months and 12 months postoperatively. Vertical bars represent SEM.
*p,0.05, Student’s t test.
Figure 3 The ratio of the visual acuity
improvement between Group N and
Group R. The improvement in visual
acuity was defined as an increase of
>0.2 logarithm of the minimum angle of
resolution (logMAR) unit, while a
decrease was defined as a reduction of .
0.2 logMAR units. *p,0.01, Mann–
Whitney U test.
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number of patients was small. Second, 30 mg of edaravone was
given for only 2 days: extending the duration of edavarone
treatment might have led to a greater improvement of the visual
acuity. In addition, combined use of edaravone with conven-
tional anticoagulants, platelet-aggregation inhibitors or anti-
VEGF treatments might also have additive and synergistic
effects.
In conclusion, vitrectomy combined with arteriovenous
sheathotomy in eyes with macular oedema due to BRVO
appeared to lead to better results then when edaravone was
given intravenously at the time of the vitrectomy. Further
studies that address the limitations discussed are necessary to
confirm the findings in this study. Edaravone should be given as
early as possible to prevent irreversible change to photoreceptors
and retinal neurons.
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